Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis.
Samar E NicolasMichael D BearAbir O KanaanOana Andreia ComanLorena DimaPublished in: American journal of therapeutics (2023)
To date, topical corticosteroids are the most commonly used agents to treat mild plaque psoriasis. Sensitive areas are often challenging to treat with existing topical therapy, including corticosteroids. Topical roflumilast has shown to be effective in treating sensitive areas, including skin folds, and may be an alternative to systemic therapy for some patients. The Food and Drug Administration approved topical roflumilast for the treatment of plaque psoriasis, including intertriginous areas, for patients 12 years or older.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- coronary artery disease
- wound healing
- peritoneal dialysis
- drug administration
- prognostic factors
- stem cells
- physical activity
- atopic dermatitis
- combination therapy
- patient reported
- cell therapy
- middle aged
- climate change
- replacement therapy
- human health